Table 2.
Association of TOP2A and FOXM1 expression with clinicopathologic factors of ccRCC patients in TMA cohort
| Factors | Case | TOP2A expression |
χ2 | P value | FOXM1 expression |
χ2 | P value | ||
|---|---|---|---|---|---|---|---|---|---|
| Low |
High |
Low |
High |
||||||
| 233(67%) | 115(33%) | 182(52%) | 166(48%) | ||||||
| Gender | |||||||||
| Male | 245 | 162 (66%) | 83 (34%) | 0.26 | 0.611 | 125 (51%) | 120 (49%) | 0.54 | 0.461 |
| Female | 103 | 71 (69%) | 32 (31%) | 57 (55%) | 46 (45%) | ||||
| Age | |||||||||
| ≤65 | 266 | 185 (70%) | 81 (30%) | 3.44 | 0.064 | 149 (56%) | 117 (44%) | 6.25 | 0.012* |
| >65 | 82 | 48 (59%) | 34 (41%) | 33 (40%) | 49 (60%) | ||||
| AJCC stage | |||||||||
| I+ II | 331 | 225 (68%) | 106 (32%) | 3.20 | 0.074 | 178 (54%) | 153 (46%) | 5.93 | 0.015* |
| III+ IV | 17 | 8 (47%) | 9 (53%) | 4 (23%) | 13 (77%) | ||||
| Tumor size(cm) | |||||||||
| ≤4 | 179 | 133 (74%) | 46 (26%) | 9.00 | 0.003* | 107 (60%) | 72 (40%) | 8.26 | 0.004* |
| >4 | 169 | 100 (59%) | 69 (41%) | 75 (44%) | 94 (56%) | ||||
| Grade | |||||||||
| I+ II | 287 | 208 (73%) | 79 (27%) | 22.55 | <0.001* | 168 (58%) | 119 (42%) | 25.54 | <0.001* |
| III+ IV | 61 | 25 (41%) | 36 (59%) | 14 (23%) | 47 (77%) | ||||
| Necrosis | |||||||||
| Yes | 62 | 26 (42%) | 36 (58%) | 21.34 | <0.001* | 22 (36%) | 40 (64%) | 8.55 | 0.003* |
| No | 286 | 207 (72%) | 79 (28%) | 160 (56%) | 126 (44%) | ||||
ccRCC: clear cell renal cell carcinoma; TMA: tissue microarray